Hosseini Mandana, Jensen Simon Storgård, Gotfredsen Klaus, Hyldahl Emil, Pedersen Anne Marie Lynge
Research Section for Oral Health, Society and Technology/Oral Rehabilitation, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Research Section for Oral Biology and Immunopathology/Oral Surgery, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Clin Oral Implants Res. 2025 Jan;36(1):51-63. doi: 10.1111/clr.14356. Epub 2024 Sep 5.
Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune disease characterized by hyposalivation. Currently, there is limited evidence for the prognosis of dental implant treatment in Sjögren's syndrome.
AIM/HYPOTHESIS: We hypothesized comparable clinical outcomes of implant-supported restorations in pSS-patients and control subjects, and improvement in oral health-related quality of life 5 years after restoration.
Patients with pSS and matched (age, gender, and tooth region) control group were recruited between June 2016 and March 2020. The clinical and radiological examination were performed, and patient-reported oral health impact profile (OHIP-49) questionnaire was used 2 months (baseline), 1, 3, and 5 years after prosthetic treatment.
We included 23 patients with pSS and 24 matched control subjects (all women, mean age: 57.1 years). The overall DMFT (decayed-missed-filled-tooth) was significantly higher (p = 0.008), symptoms of dry mouth were more severe (p = 0.001), and unstimulated and chewing-stimulated saliva flow rates were significantly lower (p < 0.001) in pSS than in control group. All implants survived with no implant mobility. At implant sites, the plaque index and probing depths did not differ (p = 0.301 and 0.446, respectively), but the gingival index was significantly higher (p = 0.003) in pSS than control group. The mean marginal bone loss, prosthetic complications, and clinician-reported aesthetic outcomes were similar in both groups after 5 years. The OHIP scores were significantly higher in the pSS than control group (p < 0.001) but reduced significantly in both groups (p = 0.026).
Replacement of missing single teeth with dental implants was successful in patients with pSS 5 years after restoration.
原发性干燥综合征（pSS）是一种以唾液分泌减少为特征的慢性全身性自身免疫性疾病。目前，关于干燥综合征患者牙种植治疗预后的证据有限。
目的/假设：我们假设pSS患者和对照组在种植体支持修复方面的临床结果具有可比性，并且修复后5年口腔健康相关生活质量会有所改善。
在2016年6月至2020年3月期间招募了pSS患者和匹配（年龄、性别和牙位）的对照组。进行了临床和影像学检查，并在修复治疗后2个月（基线）、1年、3年和5年使用患者报告的口腔健康影响概况（OHIP - 49）问卷。
我们纳入了23例pSS患者和24例匹配的对照受试者（均为女性，平均年龄：57.1岁）。pSS患者的总体龋失补牙数（DMFT）显著更高（p = 0.008），口干症状更严重（p = 0.001），非刺激性和咀嚼刺激性唾液流速显著更低（p < 0.001）。所有种植体均存活，无种植体松动。在种植部位，菌斑指数和探诊深度无差异（分别为p = 0.301和0.446），但pSS患者的牙龈指数显著高于对照组（p = 0.003）。5年后，两组的平均边缘骨吸收、修复并发症和临床医生报告的美学结果相似。pSS患者的OHIP评分显著高于对照组（p < 0.001），但两组均显著降低（p = 0.026）。
对于pSS患者，修复后5年用牙种植体替代缺失的单颗牙齿是成功的。
